LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Arteaus Therapeutics LLC
Headquarters:
Cambridge, MA, United States of America
Website:
N/A
Year Founded:
2011
Status:
Acquired
BioCentury
|
Oct 16, 2020
Deals
With Disarm deal, Atlas returns to Lilly to take neuro program forward
Eli Lilly’s acquisition of Disarm marks the second time an Atlas-incubated newco has turned to the pharma to advance its neurology assets. Under the deal, Eli Lilly and Co. (NYSE:LLY)
Read More
BioCentury
|
Apr 5, 2019
Company News
Atlas' build-to-buy Arteaus sells Emgality royalties for $260M
Read More
BioCentury
|
Aug 17, 2017
Finance
Built to purpose
How build-to-buy deals are reaching an inflection point
Read More
BioCentury
|
Jan 11, 2016
Strategy
Set them free
Why J&J may spin out core assets without claw-back agreements
Read More
BioCentury
|
Feb 5, 2015
Company News
The Medicines Co. acquires Annovation
Read More
BioCentury
|
Oct 6, 2014
Finance
Atlas' next chapter
What splitting from tech team means for Atlas life science portfolio
Read More
BioCentury
|
May 1, 2014
Strategy
Scripps looks outward
Read More
BioCentury
|
Jan 20, 2014
Company News
Arteaus Therapeutics, Eli Lilly deal
Read More
BioCentury
|
Jan 20, 2014
Finance
Asset-centric milestone
Lilly-Arteaus deal provides Atlas Venture with first asset-centric graduation
Read More
BioCentury
|
Jan 14, 2014
Company News
Lilly regains migraine compound from Atlas' Arteaus
Read More
Items per page:
10
1 - 10 of 20